Leading the Way in Life Science Technologies

GEN Exclusives

More »

Columns

More »

For full access to this article login to GEN Select now.

November 15, 2015 (Vol. 35, No. 20)

Cultivating a Drug Discovery Ecosystem

H3 Biomedicine Maintains Multiple Platforms, Generates Diverse Anticancer Drug Candidates

  • H3 Biomedicine uses a combination of genomics, synthetic organic chemistry, and tumor biology to develop small molecules for cancer treatment. According to H3’s president and CEO, Markus Warmuth, M.D., “A small molecule approach creates opportunities to go after targets that antibodies can’t tackle.” “There are only so many ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.